Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL731453 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL44083 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29412001 | 1.00 | BCL2L1 (0.47) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL22150086 | 0.87 | POLB (0.40) | BCL2L1LMNAGAA | |
| SCHEMBL28905933 | 0.86 | ALOX5 (0.49) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30566711 | 0.86 | ALOX5 (0.49) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4954902 | 0.85 | TAS1R3 (0.50) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27587691 | 0.85 | TAS1R3 (0.50) | BCL2L1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5263311 | 0.80 | CYP2A6 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL22342498 | 0.79 | MAPT (0.46) | CA12CA2CA14LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1929 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | claimed |
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-06-26 | — | — | US | claimed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | claimed |
| EP-4493273-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | Politechnika Wroclawska (PL) | 2025-01-22 | — | — | EP | claimed |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | claimed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | claimed |
| EP-4294820-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | Ohio State Innovation Foundation (US) | 2023-12-27 | — | — | EP | claimed |
| US-20230381327-A1 | REACTIVE CONJUGATES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-11-30 | — | — | US | claimed |
| WO-2023175356-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | POLITECHNIKA WROCLAWSKA (PL) | 2023-09-21 | — | — | WO | claimed |
| CN-116635408-A | Reactive conjugates | 德彪药业国际股份公司 | 2023-08-22 | — | — | CN | claimed |
| US-20020039749-A1 | High-throughput screening assays for modulators of STAT4 and STAT6 activity | AMGEN INC. | 2002-04-04 | — | — | US | claimed |
| US-6207391-B1 | INCUBATING A REACTION MIXTURE COMPRISING A STAT6 POLYPEPTIDE, A POTENTIAL BINDING MODULATOR, AND A RECEPTOR PEPTIDE WHICH COMPRISES A SPECIFIC AMINO ACID SEQUENCE | TULARIK INC. | 2001-03-27 | — | — | US | claimed |
| WO-1999050283-A1 | HIGH THROUGHPUT SCREENING ASSAYS FOR MODULATORS OF STAT4 AND STAT6 ACTIVITY | TULARIK INC. (US) | 1999-10-07 | — | — | WO | claimed |
| EP-0552417-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-07 | — | — | EP | claimed |
| EP-0833654-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | Affymax Technologies N.V. (GB) | 1998-04-08 | — | — | EP | claimed |
| EP-0528312-B1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-07-16 | — | — | EP | claimed |
| WO-1996039165-A1 | PEPTIDES AND COMPOUNDS THAT BIND TO THE IL-1 RECEPTOR | AFFYMAX TECHNOLOGIES N.V. (GB) | 1996-12-12 | — | — | WO | claimed |
| EP-0647449-A1 | Sustained-release preparation of anti-endothelin substance | Takeda Chemical Industries, Ltd. (JP) | 1995-04-12 | — | — | EP | claimed |
| EP-0552417-A1 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0528312-A2 | Cyclic peptides and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250208137-A1 | COMPOUNDS FOR THE DETECTION AND INHIBITION OF COAGULATION PROTEASES | F11, F2, F12 | BCL2L1 3504/4885HDAC3 924/4885HDAC4 736/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | BCL2L1 1772/4885HDAC3 1707/4885HDAC4 3180/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | BCL2L1 1495/4885HDAC3 1668/4885HDAC4 871/4885 |
| US-20240158445-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH THREE OR MORE HYDROPHOBIC RESIDUES | SLC3A2, SLC7A1, ARGLU1 | BCL2L1 1537/4885HDAC3 4287/4885HDAC4 4181/4885 |
| US-20230381327-A1 | REACTIVE CONJUGATES | FCGR3B, FCGR1A, FCGR2A | BCL2L1 3387/4885HDAC3 908/4885HDAC4 2471/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | BCL2L1 1495/4885HDAC3 1668/4885HDAC4 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.